Skip to main content
. Author manuscript; available in PMC: 2011 May 24.
Published in final edited form as: Clin Cancer Res. 2009 Jan 1;15(1):338–345. doi: 10.1158/1078-0432.CCR-08-1476

Fig. 3.

Fig. 3

PFS and OS in patients with MGMT-intact or MGMT-deficient neuroendocrine tumors treated with temozolomide-based therapy. A, median PFS was 19.2 mo for MGMT-deficient neuroendocrine tumors and 9.3 mo for MGMT-intact tumors (P = 0.11). B, median OS for patients with MGMT-deficient tumors was not reached; median OS for patients with MGMT-intact tumors was 19.1 mo (P = 0.14).